News & Updates

Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.

No apparent association exists between neuropsychiatric systemic lupus erythematosus (NPSLE) and known risk loci for schizophrenia in a multiethnic cohort of patients with childhood-onset (c)SLE, reveals a recent study.

Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.

Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.

Patients with psoriatic arthritis (PsA) do not appear to be at increased risk of mortality from all causes, reveals a study. Moreover, the specific proportionate mortality rate (PMR) in this cohort is similar to that of the general population.

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

Hospitalization is warranted in one in five patients with new-onset systemic lupus erythematosus (SLE) manifest disease presentations, according to a recent study. Of note, diagnosis has been delayed in nearly 20 percent of patients.